methylphenidate has been researched along with Child Development Disorders, Pervasive in 35 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Child Development Disorders, Pervasive: Severe distortions in the development of many basic psychological functions that are not normal for any stage in development. These distortions are manifested in sustained social impairment, speech abnormalities, and peculiar motor movements.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This report examined the effect of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity in a secondary analysis of RUPP Autism Network data." | 5.14 | Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. ( Aman, MG; Arnold, LE; Ghuman, J; Jahromi, LB; Kasari, CL; Kustan, E; Lee, LS; McCracken, JT; McDougle, CJ; Posey, DJ; Ritz, L; Scahill, L; Tierney, E; Vitiello, B; Witwer, A, 2009) |
| "Methylphenidate was associated with significant improvement that was most evident at the ." | 2.73 | Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. ( Aman, MG; Arnold, LE; Carroll, DH; Chuang, SZ; Cronin, P; Davies, M; McCracken, JT; McDougle, CJ; Posey, DJ; Ramadan, Y; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B; Wheeler, C; Witwer, AN; Young, C, 2007) |
| "The aim of this study was to investigate the effects of ongoing methylphenidate (MPH) on ADHD-related and autistic symptoms in Pervasive Developmental Disorders (PDD) in children who did not present any adverse effects to an initial acute dose administered at the clinic." | 2.71 | Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. ( Cianchetti, C; Di Martino, A; Melis, G; Zuddas, A, 2004) |
| "Methylphenidate was superior to placebo on the primary outcome measure, with effect sizes ranging from 0." | 2.71 | Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. ( , 2005) |
| "This report suggests that myoclonus may be a side effect of sertraline in some adolescents." | 1.31 | Myoclonus during prolonged treatment with sertraline in an adolescent patient. ( Ghaziuddin, N; Iqbal, A; Khetarpal, S, 2001) |
| " Of the patients in whom the MPD therapy was effective, the majority received a MPD dosage of 0." | 1.31 | [Methylphenidate therapy in 141 patients with hyperkinetic disorder or with pervasive developmental disorder and hyperkinesia]. ( Ishizaki, A; Sugama, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.71) | 18.7374 |
| 1990's | 2 (5.71) | 18.2507 |
| 2000's | 17 (48.57) | 29.6817 |
| 2010's | 14 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akyol Ardıç, Ü | 1 |
| Ercan, ES | 1 |
| Aygüneş, D | 1 |
| Yüce, D | 1 |
| Durak, S | 1 |
| Kosova, B | 1 |
| Reichow, B | 1 |
| Volkmar, FR | 1 |
| Bloch, MH | 1 |
| Bachmann, CJ | 1 |
| Manthey, T | 1 |
| Kamp-Becker, I | 1 |
| Glaeske, G | 1 |
| Hoffmann, F | 1 |
| Pearson, DA | 1 |
| Santos, CW | 1 |
| Aman, MG | 8 |
| Arnold, LE | 7 |
| Casat, CD | 1 |
| Mansour, R | 1 |
| Lane, DM | 1 |
| Loveland, KA | 1 |
| Bukstein, OG | 1 |
| Jerger, SW | 1 |
| Factor, P | 1 |
| Vanwoerden, S | 1 |
| Perez, E | 1 |
| Cleveland, LA | 1 |
| McCracken, JT | 6 |
| Badashova, KK | 1 |
| Posey, DJ | 4 |
| Scahill, L | 7 |
| Tierney, E | 6 |
| Vitiello, B | 7 |
| Whelan, F | 1 |
| Chuang, SZ | 2 |
| Davies, M | 2 |
| Shah, B | 3 |
| McDougle, CJ | 7 |
| Nurmi, EL | 1 |
| Fernández-Jaén, A | 1 |
| Martín Fernández-Mayoralas, D | 1 |
| Fernández-Perrone, AL | 1 |
| Calleja-Pérez, B | 1 |
| Muñoz-Jareño, N | 1 |
| López-Arribas, S | 1 |
| Dalsgaard, S | 1 |
| Nielsen, HS | 1 |
| Simonsen, M | 1 |
| Sugama, M | 4 |
| Ishizaki, A | 4 |
| Wong, IC | 1 |
| Hsia, Y | 1 |
| Jahromi, LB | 1 |
| Kasari, CL | 1 |
| Lee, LS | 1 |
| Ritz, L | 3 |
| Witwer, A | 1 |
| Kustan, E | 1 |
| Ghuman, J | 3 |
| Kawatani, M | 1 |
| Nakai, A | 1 |
| Mayumi, M | 1 |
| Hiratani, M | 1 |
| Ghuman, JK | 1 |
| Lecavalier, L | 2 |
| Riddle, MA | 1 |
| Gelenberg, A | 1 |
| Wright, R | 1 |
| Rice, S | 1 |
| Ghuman, HS | 1 |
| Fort, C | 1 |
| Murray, MJ | 1 |
| Rowles, BM | 1 |
| Findling, RL | 1 |
| Chadman, KK | 1 |
| Guariglia, SR | 1 |
| Yoo, JH | 1 |
| Di Martino, A | 1 |
| Melis, G | 1 |
| Cianchetti, C | 1 |
| Zuddas, A | 2 |
| Taylor, E | 1 |
| Döpfner, M | 1 |
| Sergeant, J | 1 |
| Asherson, P | 1 |
| Banaschewski, T | 1 |
| Buitelaar, J | 1 |
| Coghill, D | 1 |
| Danckaerts, M | 1 |
| Rothenberger, A | 1 |
| Sonuga-Barke, E | 1 |
| Steinhausen, HC | 1 |
| Williams, SK | 1 |
| Dimitropoulos, A | 1 |
| Cronin, P | 2 |
| Grados, M | 1 |
| Koenig, K | 1 |
| Lam, KS | 1 |
| McGough, J | 1 |
| Swiezy, NB | 2 |
| Dziura, J | 1 |
| Posey, D | 1 |
| Young, C | 2 |
| Ramadan, Y | 1 |
| Witwer, AN | 1 |
| Carroll, DH | 1 |
| Wheeler, C | 1 |
| Pachler, M | 1 |
| Sukhodolsky, DG | 1 |
| Gadow, KD | 1 |
| Williams White, S | 1 |
| Schmidt, K | 1 |
| Sporn, A | 1 |
| Pinsker, H | 1 |
| Weller, EB | 1 |
| Rowan, A | 1 |
| Elia, J | 1 |
| Weller, RA | 1 |
| Ghaziuddin, N | 1 |
| Iqbal, A | 1 |
| Khetarpal, S | 1 |
| Searcy, E | 1 |
| Sloman, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder[NCT05916339] | Phase 4 | 500 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder[NCT03337646] | Phase 4 | 48 participants (Actual) | Interventional | 2018-09-26 | Active, not recruiting | ||
| Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders[NCT00025779] | 60 participants | Interventional | 2001-10-31 | Completed | |||
| Quillivant XR in Children With Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study[NCT02255565] | Phase 4 | 36 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Characterization of Endogenous Melatonin Profiles in Children With Autism Spectrum Disorder.[NCT00691080] | 58 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder[NCT01238575] | Phase 4 | 62 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Neural Mechanisms of CBT for Anxiety in Children With Autism: Randomized Controlled Trial[NCT02725619] | 70 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Neural Mechanisms of Cognitive-Behavioral Therapy for Anxiety in Children With Autism Spectrum Disorder: A Pilot Study[NCT02225808] | 10 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CGI-I scale summarizes the clinician's impression of the participant's symptom improvement and ranges from 1-7 with 1 representing very much improved and 7 representing very much worse. (NCT02255565)
Timeframe: once a week for 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Very Low Dose Quillivant XR - Week 1 | 3.89 |
| Very Low Dose Quillivant XR - Week 2 | 3.56 |
| Very Low Dose Quillivant XR - Week 3 | 3.44 |
| Very Low Dose Quillivant XR - Week 4 | 3.22 |
| Very Low Dose Quillivant XR - Week 5 | 3.00 |
| Very Low Dose Quillivant XR - Week 6 | 2.89 |
| Low Dose Quillivant XR - Week 1 | 3.78 |
| Low Dose Quillivant XR - Week 2 | 3.00 |
| Low Dose Quillivant XR - Week 3 | 2.22 |
| Low Dose Quillivant XR - Week 4 | 1.63 |
| Low Dose Quillivant XR - Week 5 | 2.13 |
| Low Dose Quillivant XR - Week 6 | 2.00 |
| Moderate Dose Quillivant XR - Week 1 | 3.33 |
| Moderate Dose Quillivant XR - Week 2 | 3.11 |
| Moderate Dose Quillivant XR - Week 3 | 2.67 |
| Moderate Dose Quillivant XR - Week 4 | 2.89 |
| Moderate Dose Quillivant XR - Week 5 | 2.56 |
| Moderate Dose Quillivant XR - Week 6 | 2.22 |
The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill. (NCT02255565)
Timeframe: once a week for 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Very Low Dose Quillivant XR - Week 1 | 4.78 |
| Very Low Dose Quillivant XR - Week 2 | 4.33 |
| Very Low Dose Quillivant XR - Week 3 | 4.44 |
| Very Low Dose Quillivant XR - Week 4 | 4.33 |
| Very Low Dose Quillivant XR - Week 5 | 4.11 |
| Very Low Dose Quillivant XR - Week 6 | 4.00 |
| Low Dose Quillivant XR - Week 1 | 4.33 |
| Low Dose Quillivant XR - Week 2 | 4.00 |
| Low Dose Quillivant XR - Week 3 | 3.67 |
| Low Dose Quillivant XR - Week 4 | 2.75 |
| Low Dose Quillivant XR - Week 5 | 2.88 |
| Low Dose Quillivant XR - Week 6 | 2.78 |
| Moderate Dose Quillivant XR - Week 1 | 4.89 |
| Moderate Dose Quillivant XR - Week 2 | 4.56 |
| Moderate Dose Quillivant XR - Week 3 | 4.11 |
| Moderate Dose Quillivant XR - Week 4 | 4.00 |
| Moderate Dose Quillivant XR - Week 5 | 3.56 |
| Moderate Dose Quillivant XR - Week 6 | 3.44 |
Measures the severity of Total ADHD symptoms, Inattention and Hyperactivity/Impulsive symptoms. The Inattention and Hyperactivity/Impulsive symptoms can range from 0 to 27 each, with a higher score reflecting more severe ADHD symptoms. The total score is calculated by summing the inattention and Hyperactivity/Impulsive subscales. The total score can range from 0 to 54 with a higher score reflecting more severe ADHD symptoms. (NCT02255565)
Timeframe: once a week for 6 weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Inattention Subscale Score | Hyperactivity Subscale Score | Total Score | |
| Low Dose Quillivant XR - Week 1 | 16.33 | 15.33 | 31.67 |
| Low Dose Quillivant XR - Week 2 | 14.00 | 14.33 | 28.33 |
| Low Dose Quillivant XR - Week 3 | 12.00 | 10.22 | 22.22 |
| Low Dose Quillivant XR - Week 4 | 8.38 | 6.88 | 15.25 |
| Low Dose Quillivant XR - Week 5 | 9.50 | 9.38 | 18.88 |
| Low Dose Quillivant XR - Week 6 | 9.56 | 6.56 | 16.11 |
| Moderate Dose Quillivant XR - Week 1 | 18.11 | 12.78 | 30.89 |
| Moderate Dose Quillivant XR - Week 2 | 14.67 | 11.33 | 26.00 |
| Moderate Dose Quillivant XR - Week 3 | 13.67 | 11.78 | 25.44 |
| Moderate Dose Quillivant XR - Week 4 | 13.56 | 9.67 | 23.22 |
| Moderate Dose Quillivant XR - Week 5 | 13.00 | 9.22 | 22.22 |
| Moderate Dose Quillivant XR - Week 6 | 11.78 | 7.33 | 19.11 |
| Very Low Dose Quillivant XR - Week 1 | 17.89 | 12.44 | 30.33 |
| Very Low Dose Quillivant XR - Week 2 | 16.78 | 10.56 | 27.33 |
| Very Low Dose Quillivant XR - Week 3 | 16.67 | 11.56 | 28.22 |
| Very Low Dose Quillivant XR - Week 4 | 14.33 | 12.33 | 26.67 |
| Very Low Dose Quillivant XR - Week 5 | 14.56 | 9.22 | 23.78 |
| Very Low Dose Quillivant XR - Week 6 | 12.89 | 8.78 | 21.67 |
"The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech.~The 16-item Hyperactivity subscale covers over-activity (7 items), impulsiveness (2 items), inattention (3 items) and noncompliance (4 items). It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. The range of scores is 0 to 48." (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 34.4 |
| Inactive Placebo | 34.25 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. The 16-item Hyperactivity subscale covers over-activity (7 items), impulsiveness (2 items), inattention (3 items) and noncompliance (4 items). It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. The range of scores is 0 to 48. (NCT01238575)
Timeframe: Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 19.3 |
| Inactive Placebo | 29.7 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 12. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 4.2 |
| Inactive Placebo | 5.99 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 12. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 6.33 |
| Inactive Placebo | 6.84 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. It is a 58 item checklist which takes about 10 - 15 minutes to complete. There are five subscales: a) Irritability and Agitation b) Lethargy and Social Withdrawal c) Stereotypic Behavior d) Hyperactivity and Noncompliance and e) Inappropriate Speech. The higher the number of items (score), the greater the amount of symptoms. Scores can range from 0 to 45. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 13.5 |
| Inactive Placebo | 16.1 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. Scores for this subscale can range from 0 to 45. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 20.3 |
| Inactive Placebo | 18.06 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 48. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 9.8 |
| Inactive Placebo | 8.6 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 48. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 13.6 |
| Inactive Placebo | 12.06 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 21. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 3.6 |
| Inactive Placebo | 5.9 |
The Aberrant Behavior Checklist (ABC) is a symptom checklist for assessing problem behaviors in individuals ages 6 to 54 with mental retardation. The full ABC is a 58-item parent-rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. It has been used as a primary outcome measure in several trials of children with developmental disabilities. The interpretation of the tool and its sub-scales is that a greater number of items, indicates greater severity. This subscale's scores can range from 0 to 21. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 8.53 |
| Inactive Placebo | 9.31 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring, with a higher score indicating greater severity. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 19.00 |
| Inactive Placebo | 19.5 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring,with a higher score indicating greater severity. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 10.6 |
| Inactive Placebo | 18.7 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring, with a higher score indicating greater severity. (NCT01238575)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 14.7 |
| Inactive Placebo | 19.5 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. This subscale can range from 0 to 27 for scoring, with a higher score indicating greater severity. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 20.53 |
| Inactive Placebo | 20.41 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. The total score can range from 0 to 54, with a higher score indicating greater severity. (NCT01238575)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Extended-release Guanfacine | 39.53 |
| Inactive Placebo | 39.91 |
The ADHD Rating Scale (ADHD-RS) is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder with established reliability, validity and sensitivity to change. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. Results from this rating scale alone should not be used to make a diagnosis. The total score can range from 0 to 54, with a higher score indicating greater severity. (NCT01238575)
Timeframe: Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Extended-release Guanfacine | 25.2 |
| Inactive Placebo | 38.0 |
10 reviews available for methylphenidate and Child Development Disorders, Pervasive
| Article | Year |
|---|---|
Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Cen | 2013 |
[Autism and attention deficit hyperactivity disorder: pharmacological intervention].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2013 |
[Care continuity for patients with attention deficit hyperactivity disorder (ADHD) during transition from childhood to adulthood].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2010 |
Attention-deficit/Hyperactivity Disorder in the context of Autism spectrum disorders.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Execut | 2010 |
Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders.
Topics: Adolescent; Amphetamines; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorde | 2010 |
New directions in the treatment of autism spectrum disorders from animal model research.
Topics: Adolescent; Adolescent Behavior; Animals; Antipsychotic Agents; Aripiprazole; Brain; Central Nervous | 2012 |
Treatment of hyperactivity in children with pervasive developmental disorders.
Topics: Adrenergic alpha-Agonists; Amantadine; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2007 |
Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Child; Child D | 1999 |
Helping the patient who has pervasive developmental disorder.
Topics: Child; Child Development Disorders, Pervasive; Communication; Diagnosis, Differential; Haloperidol; | 2001 |
Use of medication in pervasive developmental disorders.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Child; Child | 1991 |
7 trials available for methylphenidate and Child Development Disorders, Pervasive
| Article | Year |
|---|---|
Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Devel | 2013 |
Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity.
Topics: Adolescent; Asperger Syndrome; Autistic Disorder; Central Nervous System Stimulants; Child; Child De | 2009 |
Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Child Development Disorders, Pervasive; | 2009 |
Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Child Development Disorders, Pervasive; | 2009 |
Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Child Development Disorders, Pervasive; | 2009 |
Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Child Development Disorders, Pervasive; | 2009 |
Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System | 2004 |
Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2005 |
Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.
Topics: Antipsychotic Agents; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasi | 2006 |
Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2007 |
18 other studies available for methylphenidate and Child Development Disorders, Pervasive
| Article | Year |
|---|---|
[Response With Methylphenidate to ADHD-Like Symptoms in Pervasive Developmental Disorder: Does CES-1 Enzyme Gene Polymorphism Have a Role?]
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Carboxylic Ester Hydrolases; Central Nerv | 2017 |
Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Autistic Disorder; Central Nervous System Stimula | 2013 |
Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders.
Topics: Attention Deficit Disorder with Hyperactivity; Biogenic Monoamines; Central Nervous System Stimulant | 2014 |
Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish registe
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2013 |
[Drug therapy for AD/HD investigation of usefulness of extended-release methylphenidate and atomoxetine from the viewpoint of persistency rate].
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child D | 2014 |
Authors' response to Bachmann and Hoffman's comments on psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study.
Topics: Child Development Disorders, Pervasive; Female; Humans; Male; Methylphenidate; Risperidone; Valproic | 2015 |
Recent NIMH clinical trials and implications for practice.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 2008 |
[Retrospective analysis of pervasive developmental disorder patients initially diagnosed with attention deficit/hyperactivity disorder].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Child, | 2009 |
[Clinical assessment of the effect of switch from immediate-release to extended-release methylphenidate in 181 patients with isolated attention deficit/hyperactivity disorder (AD/HD) or AD/HD associated with pervasive developmental disorder].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Perva | 2009 |
Academy of Medicine Singapore-Ministry of Health clinical practice guidelines: Autism Spectrum Disorders in pre-school children.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Benzodiazepines; Central Nervous System Sti | 2010 |
European clinical guidelines for hyperkinetic disorder -- first upgrade.
Topics: Alleles; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Ch | 2004 |
Methylphenidate an effective treatment for ADHD?
Topics: Adrenergic alpha-Agonists; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Auti | 2004 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2006 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
The effect of stimulant medication in childhood-onset pervasive developmental disorder--a case report.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Humans | 1982 |
Use of stimulant medication in treating pervasive developmental disorder.
Topics: Adult; Child Development Disorders, Pervasive; Female; Humans; Methylphenidate | 1981 |
Myoclonus during prolonged treatment with sertraline in an adolescent patient.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents, Second-Generation; Attention Deficit Disorder wi | 2001 |
[Methylphenidate therapy in 141 patients with hyperkinetic disorder or with pervasive developmental disorder and hyperkinesia].
Topics: Adolescent; Adult; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; | 2001 |